Phase IB study on prevention of surgery-induced immunodeficiency with preoperative administration of low-dose subcutaneous interleukin-2 in gastric cancer patients

Journal of Surgical Oncology

Volumn 78, Issue 1, 2001, Pages 32-37

  Cerea, K ^a   Romano, F ^a   Bravo, A F ^a   Motta, V ^a   Uggeri, F ^a   Brivio, F ^a   Fumagalli, L A ^a   Uggeri, D ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

Cancer immunodeficiency; Gastric cancer; Interleukin 2; Postoperative lymphocytopenia; Preoperative administration

Indexed keywords

INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; FEMALE; FEVER; HELPER CELL; HUMAN; IMMUNE DEFICIENCY; LYMPHOCYTOPENIA; MALE; OUTPATIENT CARE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH CANCER; T LYMPHOCYTE SUBPOPULATION;

ADENOCARCINOMA; ADULT; AGED; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTRECTOMY; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; MALE; MIDDLE AGED; PREOPERATIVE CARE; STOMACH NEOPLASMS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 0034868414     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.1120     Document Type: Article

References (27)

1. Lower survival in metastatic cancer patients with reduced interleukin-2 blood concentrations
2. Decreased IL-2 production in patients with gastrointestinal cancer
3. Prognostic signifiance of peripheral lynphocite counts and carcinoembryonic antigens in colorectal carcinoma
4. Prognostic factors for survival in patients with inoperable lung cancer
5. Soluble Interlukin-2 receptor, CD4 and CD8 levels in melanoma: A longitudinal study
6. Lymphocyte subsets as prognostic markers for cancer patients receiving immunomodulative therapy
7. Studies in prognostic factors relating to chemotherapy for advanced gastric cancer
8. Association of a circulating immunosoppressive polypeptide with operative and accidental trauma
9. Generation of suppressor cells for natural killer activity in cancer after surgery
10. Surgery, trauma and immune suppression
11. Prognostic factors in colorectal carcinoma: Significance of peripheral T lymphocytes
12. Subcutaneous administration of interleukin-2 in human immunodeficiency virus-type-1 infected persons
13. Effects of a perioperative course of interleukin-2 on surgical and immunobiological variables in patients with colorectal cancer: A phase 2 study
14. Pharmacokinetics of recombinant interleukin-2 in humans
15. The lympahtic route. VII. Distribution of recombinant human interleukin-2 in rabbit plasma and lymph
16. Timing and schedule of perioperative immunotherapy with interleukin-2 in oncological surgery
17. Design of clinical trials biological response modifiers
18. Redistribution of lymphocytes after major surgical stress
19. In vitro T-cell function, delayed-type hypersensitivity skin testing and CD4+ T-cell subsets phenotyping independently predict survival time in patients infected with human immunodeficiency virus
20. Phase I-II randomized study on prehepatectomy recombinant human interleukin-2 immunotherapy in patients with metastatic carcinoma of the colon and rectum
21. Phase II randomized study of peroperative IL-2 administration in operable NSCLC
22. Preoperative rIL-2 treatement in renal cancer: Early and late effects on lymphocyte subsets and proliferation, NK acivity, IL-6 in vivo and in vitro production
23. Preoperative interleukin-2 subcutaneus immunotherapy may prolong the survival time in advanced colorectal cancer patients
24. The interleukin-2 T cell system: A new cell growth model
25. Postoperative morbidity and mortality after D1 and D2 resection for gastric cancer. Preliminary results of the MRC randomized controlled surgical trial
26. Extended lymphnode dissection for gastric cancer: Results of a prospective, multi-center analysis of morbidity and mortality in 118 consecutive cases
27. Special article outcomes of cancer treatments for technology assessments and cancer treatments guidelines